HC Wainwright reaffirmed their buy rating on shares of InflaRx (NASDAQ:IFRX - Free Report) in a research note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price target on the stock.
InflaRx Stock Down 1.9 %
NASDAQ:IFRX traded down $0.03 during midday trading on Monday, hitting $1.53. The company had a trading volume of 136,484 shares, compared to its average volume of 153,888. InflaRx has a 52-week low of $1.17 and a 52-week high of $2.10. The stock's fifty day moving average price is $1.53 and its 200-day moving average price is $1.51. The company has a market capitalization of $90.09 million, a PE ratio of -1.42 and a beta of 1.57.
InflaRx (NASDAQ:IFRX - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). InflaRx had a negative return on equity of 47.03% and a negative net margin of 44,046.09%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.04 million. As a group, research analysts forecast that InflaRx will post -0.98 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC boosted its holdings in InflaRx (NASDAQ:IFRX - Free Report) by 2.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 704,987 shares of the company's stock after purchasing an additional 16,383 shares during the period. Ikarian Capital LLC owned approximately 1.20% of InflaRx worth $1,086,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.39% of the company's stock.
About InflaRx
(
Get Free Report)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Further Reading
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
